On Tuesday, Mineralys Therapeutics Inc (NASDAQ: MLYS) was -5.30% drop from the session before settling in for the closing price of $9.25. A 52-week range for MLYS has been $8.58 – $16.91.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -7.43%. With a float of $24.55 million, this company’s outstanding shares have now reached $49.82 million.
The extent of productivity of a business whose workforce counts for 51 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Mineralys Therapeutics Inc stocks. The insider ownership of Mineralys Therapeutics Inc is 50.67%, while institutional ownership is 55.68%. The most recent insider transaction that took place on Jan 13 ’25, was worth 97,864. In this transaction CFO and Secretary of this company sold 10,757 shares at a rate of $9.10, taking the stock ownership to the 226,097 shares. Before that another transaction happened on Jan 13 ’25, when Company’s Chief Executive Officer sold 18,333 for $9.06, making the entire transaction worth $166,082. This insider now owns 877,608 shares in total.
Mineralys Therapeutics Inc (MLYS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.10% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
You can see what Mineralys Therapeutics Inc (MLYS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.64, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -3.75 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
The latest stats from [Mineralys Therapeutics Inc, MLYS] show that its last 5-days average volume of 0.47 million was superior to 0.31 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 19.50%. Additionally, its Average True Range was 0.74.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 7.40%, which indicates a significant decrease from 18.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.15% in the past 14 days, which was lower than the 68.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.79, while its 200-day Moving Average is $12.18. Now, the first resistance to watch is $9.28. This is followed by the second major resistance level at $9.81. The third major resistance level sits at $10.33. If the price goes on to break the first support level at $8.24, it is likely to go to the next support level at $7.72. The third support level lies at $7.20 if the price breaches the second support level.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
There are 49,836K outstanding shares of the company, which has a market capitalization of 436.56 million. As of now, sales total 0 K while income totals -177,810 K. Its latest quarter income was 0 K while its last quarter net income were -48,950 K.
